These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26999093)

  • 21. Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
    Arias DG; Herrera FE; Garay AS; Rodrigues D; Forastieri PS; Luna LE; Bürgi MD; Prieto C; Iglesias AA; Cravero RM; Guerrero SA
    Eur J Med Chem; 2017 Jan; 125():1088-1097. PubMed ID: 27810595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrazol(in)e derivatives of curcumin analogs as a new class of anti-
    Matiadis D; Saporiti T; Aguilera E; Robert X; Guillon C; Cabrera N; Pérez-Montfort R; Sagnou M; Alvarez G
    Future Med Chem; 2021 Apr; 13(8):701-714. PubMed ID: 33648346
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-
    Martinez-Peinado N; Martori C; Cortes-Serra N; Sherman J; Rodriguez A; Gascon J; Alberola J; Pinazo MJ; Rodriguez-Cortes A; Alonso-Padilla J
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new chemotype with promise against Trypanosoma cruzi.
    Wang X; Cal M; Kaiser M; Buckner FS; Lepesheva GI; Sanford AG; Wallick AI; Davis PH; Vennerstrom JL
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126778. PubMed ID: 31706668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial disfunction and ROS production are essential for anti-Trypanosoma cruzi activity of β-lapachone-derived naphthoimidazoles.
    Bombaça ACS; Viana PG; Santos ACC; Silva TL; Rodrigues ABM; Guimarães ACR; Goulart MOF; da Silva Júnior EN; Menna-Barreto RFS
    Free Radic Biol Med; 2019 Jan; 130():408-418. PubMed ID: 30445126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discovery.
    Gupta S; Igoillo-Esteve M; Michels PA; Cordeiro AT
    Mol Biol Int; 2011; 2011():135701. PubMed ID: 22091394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiparasitic effect of (-)-α-bisabolol against Trypanosoma cruzi Y strain forms.
    de Menezes RRPPB; Sampaio TL; Lima DB; Sousa PL; de Azevedo IEP; Magalhães EP; Tessarolo LD; Marinho MM; Dos Santos RP; Martins AMC
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114860. PubMed ID: 31353066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors.
    Pauli I; Ferreira LG; de Souza ML; Oliva G; Ferreira RS; Dessoy MA; Slafer BW; Dias LC; Andricopulo AD
    Future Med Chem; 2017 May; 9(7):641-657. PubMed ID: 28509592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design.
    Aronov AM; Verlinde CL; Hol WG; Gelb MH
    J Med Chem; 1998 Nov; 41(24):4790-9. PubMed ID: 9822549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
    Suto Y; Nakajima-Shimada J; Yamagiwa N; Onizuka Y; Iwasaki G
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2967-71. PubMed ID: 26037321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
    Chen CK; Doyle PS; Yermalitskaya LV; Mackey ZB; Ang KK; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2009; 3(2):e372. PubMed ID: 19190730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro anti-Trypanosoma cruzi activity of ternary copper(II) complexes and in vivo evaluation of the most promising complex.
    Paixão DA; Lopes CD; Carneiro ZA; Sousa LM; de Oliveira LP; Lopes NP; Pivatto M; Chaves JDS; de Almeida MV; Ellena J; Moreira MB; Netto AVG; de Oliveira RJ; Guilardi S; de Albuquerque S; Guerra W
    Biomed Pharmacother; 2019 Jan; 109():157-166. PubMed ID: 30396072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, molecular modelling, and in vitro evaluation of tricyclic coumarins against Trypanosoma cruzi.
    Coelho GS; Andrade JS; Xavier VF; Sales Junior PA; Rodrigues de Araujo BC; Fonseca KDS; Caetano MS; Murta SMF; Vieira PM; Carneiro CM; Taylor JG
    Chem Biol Drug Des; 2019 Mar; 93(3):337-350. PubMed ID: 30362274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme.
    Uchiyama N; Kabututu Z; Kubata BK; Kiuchi F; Ito M; Nakajima-Shimada J; Aoki T; Ohkubo K; Fukuzumi S; Martin SK; Honda G; Urade Y
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5123-6. PubMed ID: 16304182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
    Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
    Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterobimetallic nickel(II) and palladium(II) complexes derived from S-benzyl-N- (ferrocenyl)methylenedithiocarbazate: Trypanocidal activity and interaction with Trypanosoma cruzi Old Yellow Enzyme (TcOYE).
    Carneiro ZA; Lima JC; Lopes CD; Gaspari APS; de Albuquerque S; Dinelli LR; Veloso-Silva LLW; Paganelli MO; Libardi SH; Oliveira CG; Deflon VM; Oliveira RJ; Borges JC; Maia PIS
    Eur J Med Chem; 2019 Oct; 180():213-223. PubMed ID: 31306908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
    Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Inhibitors to
    Matutino Bastos T; Botelho Pereira Soares M; Haddad Franco C; Alcântara L; Antonini L; Sabatino M; Mautone N; Holanda Freitas-Junior L; Moraes CB; Ragno R; Rotili D; Schenkman S; Mai A; Silvio Moretti N
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ubiquinone synthesis pathway is a promising drug target for Chagas disease.
    Nara T; Nakagawa Y; Tsuganezawa K; Yuki H; Sekimata K; Koyama H; Ogawa N; Honma T; Shirouzu M; Fukami T; Matsuo Y; Inaoka DK; Kita K; Tanaka A
    PLoS One; 2021; 16(2):e0243855. PubMed ID: 33539347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and structural characterization of an ecotin-like serine protease inhibitor from Trypanosoma cruzi.
    Garcia FB; Cabral AD; Fuhlendorf MM; da Cruz GF; Dos Santos JV; Ferreira GC; de Rezende BRC; Santana CM; Puzer L; Sasaki SD; Garcia W; Sperança MA
    Int J Biol Macromol; 2020 May; 151():459-466. PubMed ID: 32084472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.